Jeff Yass’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$218K Sell
80,000
-1,900
-2% -$6.34K ﹤0.01% 11754
2026
Q2
$307K Sell
81,900
-825,900
-91% -$3.15M ﹤0.01% 10990
2026
Q1
$4.27M Buy
907,800
+887,200
+4,307% +$4.5M ﹤0.01% 4531
2025
Q4
$87.8K Sell
20,600
-181,200
-90% -$688K ﹤0.01% 11525
2025
Q3
$644K Buy
201,800
+186,900
+1,254% +$421K ﹤0.01% 8398
2025
Q2
$33.8K Buy
+14,900
New +$24K ﹤0.01% 12223
2024
Q3
– Sell
-15,300
Closed -$18.7K – 12133
2024
Q2
$18.7K Buy
+15,300
New +$30.5K ﹤0.01% 11678
2023
Q2
– Sell
-28,000
Closed -$42.3K – 12204
2023
Q1
$42.3K Buy
+28,000
New +$63.3K ﹤0.01% 11758
2022
Q1
– Sell
-21,700
Closed -$94K – 13112
2021
Q4
$94K Sell
21,700
-9,900
-31% -$58K ﹤0.01% 12183
2021
Q3
$161K Buy
31,600
+4,200
+15% +$22.5K ﹤0.01% 11733
2021
Q2
$173K Buy
27,400
+6,400
+30% +$49.8K ﹤0.01% 11737
2021
Q1
$162K Buy
+21,000
New +$166K ﹤0.01% 11589
2018
Q4
– Sell
-24,800
Closed -$459K – 9060
2018
Q3
$459K Buy
24,800
+13,400
+118% +$305K ﹤0.01% 6693
2018
Q2
$261K Buy
+11,400
New +$291K ﹤0.01% 8115

Other funds holding CTMX

Jeff Yass's CTMX Position: Q3 2026 in Review

Jeff Yass increased its CytomX Therapeutics (CTMX) stake by 1,051% in Q3 2026, buying an estimated $3.18M and bringing the position to 1,043,451 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #5528.

Jeff Yass first reported a position in CTMX in Q4 2015 and has held it in 32 quarters since. The position peaked at $8.79M in Q1 2026. 193 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Jeff Yass held 1,043,451 shares of CytomX Therapeutics worth $2.84M as of Q3 2026.
  • Jeff Yass bought 952,778 CytomX Therapeutics shares in Q3 2026, an estimated $3.18M.
  • CytomX Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #5528 holding.
  • Jeff Yass first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Jeff Yass's CytomX Therapeutics position peaked at $8.79M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.